RT Journal Article
SR Electronic
T1 VIDAS<sup>®</sup> TB-IGRA accuracy in tuberculosis patients and persons at varying risk of exposure
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.03.24309158
DO 10.1101/2024.07.03.24309158
A1 Goletti, Delia
A1 Banaei, Niaz
A1 Batra, Rahul
A1 Berger, Anne Emmanuelle
A1 Blazevic, Azra
A1 Botelho-Nevers, Elisabeth
A1 Breen, Ronan
A1 Bruiners, Natalie
A1 Cambau, Emmanuelle
A1 Carbonnelle, Etienne
A1 Daley, Charles L.
A1 Descotes-Genon, Cécile
A1 Gennaro, Francesco Di
A1 Doucet-Populaire, Florence
A1 Esmail, Aliasgar
A1 Estrada Guzman, Julia Dolores
A1 Fontana, Luc
A1 Gennaro, Maria Laura
A1 Handler, Deborah
A1 Herrera Torres, Rosa María
A1 Hoft, Daniel
A1 Ismail, Nahed
A1 Isnard, Margaux
A1 Lardizabal, Alfred
A1 Lesage, François Xavier
A1 Lopes, Amanda
A1 López Vidal, Williams Luciano
A1 Contreras, Rene Machado
A1 Manivet, Philippe
A1 Marotte, Hubert
A1 Méchaï, Frédéric
A1 Medjahed-Artebasse, Amel
A1 Meldau, Richard
A1 Mérieux, Yves
A1 Morel, Jacques
A1 Mougari, Faiza
A1 Oelofse, Suzette
A1 Palmieri, Fabrizio
A1 Perrot, Jean Luc
A1 Petruccioli, Elisa
A1 Pride, David T.
A1 Tuaillon, Edouard
A1 Upton, Caryn
A1 Vanker, Naadira
A1 Dheda, Keertan
YR 2024
UL http://medrxiv.org/content/early/2024/07/05/2024.07.03.24309158.abstract
AB Background Detection and treatment of individuals with presumed latent tuberculosis (TB) infection (i.e., excluding active disease; LTBI) is imperative to achieve global TB control, as they represent a potential transmission reservoir. However, more sensitive and user-friendly diagnostic tools are needed.Methods We evaluated the accuracy for TB infection detection of the new VIDAS® TB-IGRA (bioMérieux), a fully automated, single tube (thus eliminating the need for batch testing) overnight incubation assay, compared to the QuantiFERON®-TB Gold Plus (QFT-Plus, QIAGEN), in a global multi-centre cross-sectional study (NCT04048018) that included patients with TB disease (n=200) or participants at varying levels of TB exposure (n=1460; mixed exposure-risk-population).Results VIDAS® TB-IGRA identified TB disease with greater sensitivity than QFT-Plus (97.5% vs. 80.7%, P&lt;0.01%), and yielding significantly fewer false-negatives (2.5% vs. 17.5%; P&lt;0.01%) and indeterminate results (1.0% vs. 9.5%; P=0.02%). In the mixed exposure-risk-population, negative (NPA) and positive percent agreement (PPA) were 90.1% (1097/1217) and 92.1% (223/242), respectively. PPA increased with TB-exposure risk (up to 95.7% for high-risk participants), whereas NPA decreased (starting from 96.9% for low-risk participants). Regression analyses revealed that VIDAS® TB-IGRA had a better fit with the risk-exposure gradient than the QFT-Plus. Specificity in extremely low TB-exposure risk participants (n = 125) was high for both VIDAS® TB-IGRA and QFT-Plus (97.6% vs. 95.2%; P=8.33%).Conclusions VIDAS® TB-IGRA displayed greater sensitivity than QFT-Plus, had a lower indeterminate rate, correlated better with an exposure gradient, and was highly specific, suggesting that it is a potentially valuable tool for the diagnosis of LTBI.Take-home message The first fully automated interferon-γ-release assay—the bioMérieux VIDAS® TB-IGRA—is highly specific and displays greater sensitivity than QuantiFERON®-TB Gold Plus, and thus represents a valuable new and streamlined diagnostic tool for TB infection.Competing Interest StatementAll authors had financial support from bioMérieux for performing this study.Clinical TrialNCT04048018Funding StatementThis study was funded by bioMérieuxAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The following gave ethical approval for this work: - The French National Ethics committee (CPP, ref. 2019-A00998-49) - The UK Health Research Authority (Wales Research Ethics Committee 7, REC refs: 19/WA/0284 and 19/WA/0285) - The INMI "L. Spallanzani" (Rome, Italy) Ethics Committee (approval n°35/2019) - The "Comité de Ética en Investigación del Hospital General de Mexicali" (Mexico, ref. 02-01-HGMXL/FMED-UABC-2019-08-29-254) - In South Africa: - Pharma ethics refs. 190822774 and 190822777 - University of Cape Town Human Research Ethics Committee ref. 840/2019 - In USA: - Western Institutional Review Board (WIRB, tracking numbers: 20191965; 20192037; 20192039) - The Rutgers University Institutional Review Board (Refs: Pro2019001840 and Pro2019001936) - The Stanford University Institutional Review Board (eProtocol number: 53485) - The University of Illinois at Chicago Institutional Review Board (research protocol number: 2019-1145)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors